What is Kaleo?
Founded in 2005, Kaleo operates within the pharmaceutical and related products industry. The company's focus on manufacturing pharmaceuticals positions it within a highly regulated and competitive market. Its established presence since 2005 suggests a mature operational framework and a sustained commitment to its product lines. The recent strategic investment signals confidence from backers in Kaleo's business model and future prospects, likely aimed at enhancing its manufacturing capabilities, expanding its product portfolio, or entering new markets.
How much funding has Kaleo raised?
Kaleo has raised a total of $165M across 2 funding rounds:
Debt
$15M
Debt
$150M
Debt (2012): $15M with participation from Hercules Technology Growth Capital
Debt (2014): $150M led by PDL BioPharma
Key Investors in Kaleo
PDL BioPharma
PDL BioPharma manages a portfolio of patents and royalty assets, specializing in licensing agreements with biotechnology and pharmaceutical companies. Their involvement suggests a strategic interest in Kaleo's intellectual property or market access.
Hercules Technology Growth Capital
Hercules Capital is a specialty finance company providing venture growth loans to high-growth, innovative companies across technology and life sciences. Their participation indicates support for Kaleo's growth phase through debt financing.
What's next for Kaleo?
The substantial enterprise-level funding, coupled with the recent strategic investment, positions Kaleo for significant advancements. This capital infusion is expected to fuel innovation in pharmaceutical development, potentially leading to the launch of new therapies or the enhancement of existing ones. The company may leverage this financing to scale its manufacturing operations, invest in research and development, or pursue strategic partnerships. Kaleo's trajectory suggests a focus on solidifying its market position and driving long-term value through strategic capital deployment.
See full Kaleo company page
